SynthesisThe British journal of radiology2017
A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.
Synthesis in The British journal of radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 81 citations in OpenAlex.
- Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.Current oncology (Toronto, Ont.) · 2021Trial
- Development and external validation of a FDG PET-based radiomics model predicting occult lymph node metastasis in non-small cell lung cancer patients.European journal of nuclear medicine and molecular imaging · 2026Article
- The Fibrotic-Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges.Life (Basel, Switzerland) · 2026Review
- Small-volume plan optimization of inoperable early-stage centrally-located non-small-cell lung cancer using VMAT-based SBRT under the DIBH scenario: a single-arc model or a dual-arc plan?Frontiers in oncology · 2026Article
- Markerless tumor tracking for lung SBRT with the Radixact Synchrony system: Initial experience and short-term clinical outcomes.Journal of applied clinical medical physics · 2025Article
- Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival.Clinical and translational radiation oncology · 2025Article
- Comprehensive end-to-end dosimetry audit for stereotactic body radiotherapy in spine, lung, and soft tissue.Journal of applied clinical medical physics · 2025Article
- Article
- Clinical effects of re-evaluating a lung SBRT failure mode and effects analysis in a radiotherapy department.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Comparative analysis of delivered and planned doses in target volumes for lung stereotactic ablative radiotherapy.Radiation oncology (London, England) · 2024Article
- Article
- Dosimetric investigation of couch rotation angles in non-coplanar VMAT plans for lung cancer SBRT.Frontiers in oncology · 2024Article
- Article
- Evaluation of tumour motion and internal/external correlation in lung SABR.The British journal of radiology · 2023Article
- Article
- Review
- The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer.Frontiers in oral health · 2023Review
- Article
- Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.Journal of cancer research and clinical oncology · 2022Article
- Applying PET-CT for predicting the efficacy of SBRT to inoperable early-stage lung adenocarcinoma: A Brazilian case-series.Lancet regional health. Americas · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy (RT) technique where high doses of radiation are precisely delivered to an extracranial target within the body, using either a single fraction of RT or using multiple small numbers of fractions. SABR has now become the standard of care treatment for patients with early-stage non-small-cell lung cancer (NSCLC) for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early-stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or RT, and future potential drug combinations with SABR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.